| Dr Allison Bock, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Dr Allison Bock |
|---|---|
| Gender | Female |
| Speciality | Hematology |
| Experience | 7 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003347097 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0000X | Internal Medicine - Hematology | 13278691-1205 (Utah) | Primary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 67073 (Minnesota) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Utah Hospitals And Clinics | Salt lake city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Utah Adult Services | 0941525273 | 1459 |
News Archive
A team of researchers at the Icahn School of Medicine at Mount Sinai and the University of Washington has designed a modeling system that integrates genomic and temporal information to infer causal relationships between genes, drugs, and their environment, allowing for a more accurate prediction of their interactions over time.
A new invention may be on the verge of replacing a costly cranial surgical procedure currently being performed on some traffic accident victims and other patient groups. The ultrasound-based technology has now been granted CE approval for the European market.
Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.
Washington State University researchers have developed an easy-to-use software program to identify drug-resistant genes in bacteria.
› Verified 8 days ago
| Entity Name | University Of Utah Adult Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
A team of researchers at the Icahn School of Medicine at Mount Sinai and the University of Washington has designed a modeling system that integrates genomic and temporal information to infer causal relationships between genes, drugs, and their environment, allowing for a more accurate prediction of their interactions over time.
A new invention may be on the verge of replacing a costly cranial surgical procedure currently being performed on some traffic accident victims and other patient groups. The ultrasound-based technology has now been granted CE approval for the European market.
Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.
Washington State University researchers have developed an easy-to-use software program to identify drug-resistant genes in bacteria.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Allison Bock, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Dr Allison Bock, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
A team of researchers at the Icahn School of Medicine at Mount Sinai and the University of Washington has designed a modeling system that integrates genomic and temporal information to infer causal relationships between genes, drugs, and their environment, allowing for a more accurate prediction of their interactions over time.
A new invention may be on the verge of replacing a costly cranial surgical procedure currently being performed on some traffic accident victims and other patient groups. The ultrasound-based technology has now been granted CE approval for the European market.
Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.
Washington State University researchers have developed an easy-to-use software program to identify drug-resistant genes in bacteria.
› Verified 8 days ago
Emily Leasure, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jorge A Velosa, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michael Ruediger Mueller, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mr. Karun Singh Badwal, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michal Reid, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Katherine Desprez Wick, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |